[go: up one dir, main page]

PE20181166A1 - Uso de trientina para el suministro de cobre a un tejido isquemico - Google Patents

Uso de trientina para el suministro de cobre a un tejido isquemico

Info

Publication number
PE20181166A1
PE20181166A1 PE2018000421A PE2018000421A PE20181166A1 PE 20181166 A1 PE20181166 A1 PE 20181166A1 PE 2018000421 A PE2018000421 A PE 2018000421A PE 2018000421 A PE2018000421 A PE 2018000421A PE 20181166 A1 PE20181166 A1 PE 20181166A1
Authority
PE
Peru
Prior art keywords
copper
ischemic tissue
trientine
supply
repair
Prior art date
Application number
PE2018000421A
Other languages
English (en)
Inventor
Yujian James Kang
Original Assignee
Innolife Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innolife Co Ltd filed Critical Innolife Co Ltd
Publication of PE20181166A1 publication Critical patent/PE20181166A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Procedimientos de reparacion y regeneracion de un tejido isquemico mediante la estimulacion de la redistribucion y del uso de nuevo de cobre administrando una composicion que comprende una tetramina quelante del cobre, tal como la trientina. Procedimientos y composiciones para el aumento del nivel de cobre intracelular y/o la induccion de la reparacion de un tejido isquemico en un individuo. El aumento del nivel de cobre en un tejido isquemico puede estimular las actividades transcripcionales del HIF-1 dependientes del cobre y la reparacion tisular.
PE2018000421A 2015-09-24 2016-09-23 Uso de trientina para el suministro de cobre a un tejido isquemico PE20181166A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2015/090528 WO2017049529A1 (en) 2015-09-24 2015-09-24 A pharmaceutical composition comprising a copper chelating tetramine and the use thereof

Publications (1)

Publication Number Publication Date
PE20181166A1 true PE20181166A1 (es) 2018-07-19

Family

ID=58385664

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018000421A PE20181166A1 (es) 2015-09-24 2016-09-23 Uso de trientina para el suministro de cobre a un tejido isquemico

Country Status (18)

Country Link
US (2) US11033579B2 (es)
EP (1) EP3352743A4 (es)
JP (1) JP7041053B2 (es)
KR (1) KR20180055877A (es)
CN (2) CN108697669B (es)
AU (1) AU2016328156B2 (es)
CA (1) CA2998958C (es)
CL (1) CL2018000742A1 (es)
CO (1) CO2018004189A2 (es)
EA (1) EA037045B1 (es)
EC (1) ECSP18031122A (es)
HK (1) HK1259032A1 (es)
IL (1) IL257904B (es)
MX (1) MX391462B (es)
NZ (1) NZ740728A (es)
PE (1) PE20181166A1 (es)
UA (1) UA123503C2 (es)
WO (2) WO2017049529A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016168993A1 (en) 2015-04-22 2016-10-27 Innolife Co., Ltd. Methods of tissue repair and regeneration
WO2017049529A1 (en) 2015-09-24 2017-03-30 Innolife Co., Ltd. A pharmaceutical composition comprising a copper chelating tetramine and the use thereof
US20220331275A1 (en) * 2019-06-17 2022-10-20 Philera New Zealand Ltd. Combination treatments for central nervous system disorders
KR102508657B1 (ko) * 2021-02-17 2023-03-10 성균관대학교산학협력단 금-구리 나노입자를 유효성분으로 포함하는 허혈성 질환 예방 또는 치료용 조성물
AU2022231038A1 (en) * 2021-03-05 2023-09-21 Philera New Zealand Ltd. Treatment of copper disorders
AU2023332633A1 (en) * 2022-08-27 2025-04-03 Biophore India Pharmaceuticals Pvt. Ltd Trientine liquid dosage forms
CN115554473A (zh) * 2022-10-25 2023-01-03 华中科技大学同济医学院附属协和医院 去细胞心脏瓣膜复合材料及其制备方法和应用
WO2024231774A1 (en) 2023-05-05 2024-11-14 Cong Nhan Huynh Pharmaceuticals containing chelators with strong zn ions-holding feature for the treatment of symptoms and diseases caused by microorganisms/diseases caused by toxins or neurotoxins/cancer/several syndromes

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4012221A (en) 1975-05-13 1977-03-15 International Copper Research Association Inc. Slow release copper toxicant compositions
US4952607A (en) 1982-05-27 1990-08-28 International Copper Research Association, Inc. Copper complex for treating cancer
WO1984004922A1 (en) 1983-06-10 1984-12-20 Int Copper Ass Inc Copper complex for treating cancer
CA1244764A (en) 1984-06-04 1988-11-15 Randall K. Johnson Tumor cell growth-inhibiting pharmaceutical compositions containing phosphino-hydrocarbon-gold, silver or copper complexes
US4550209A (en) 1984-07-26 1985-10-29 Texaco Inc. Process for the preparation of linear polyethylenepolyamines by reacting monoethanolamine with ethylenediamine in the presence of an intercalatively active catalyst
US5037812A (en) 1985-04-02 1991-08-06 Smithkline Beckman Corporation Tumor cell growth-inhibiting pharmaceutical compositions containing phosphino-hydrocarbon-gold, silver or copper complexes
US4806517A (en) 1986-01-21 1989-02-21 Texaco Inc. Method for making pelleted phosphated catalysts derived from group IVB transition metal oxides and catalysts thus prepared
US4766247A (en) 1986-09-26 1988-08-23 Air Products And Chemicals, Inc. Color reduction of polyamines by mild catalytic hydrogenation
US5385933A (en) 1989-02-27 1995-01-31 The United States Of America As Represented By The Department Of Health And Human Services Method for the treatment of cancer by use of the copper complex of S-(methylthio)-DL-homocysteine or the L-enantiomorph thereof
US5124351A (en) 1989-02-27 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pharmaceutical compositions for the treatment of cancers susceptible to treatment with the copper complex of S-(methylthio)-DL-homocysteine or the L-enantimorph thereof
MX172248B (es) 1989-12-20 1993-12-09 Univ Mexico Procedimiento para la obtencion de nuevos complejos aminoacidatos de cobre mixtos a base de fenantrolinas feniladas como agentes anticancerigenos
US5164367A (en) 1990-03-26 1992-11-17 Procyte Corporation Method of using copper(ii) containing compounds to accelerate wound healing
US5225599A (en) 1990-03-30 1993-07-06 Union Carbide Chemicals & Plastics Technology Corporation Selective production of linear triethylenetetramine and aminoethylethanolamine
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
US5480975A (en) 1994-02-08 1996-01-02 Brigham And Women's Hospital Induction of vascular endothelial growth factor (VEGF) by transition metals
US6706759B1 (en) 1998-09-08 2004-03-16 Charlotte-Mecklenburg Hospital Authority Method of treating cancer using dithiocarbamate derivatives
US6589987B2 (en) 1998-09-08 2003-07-08 Charlotte-Mecklenburg Hospital Authority Method of treating cancer using tetraethyl thiuram disulfide
US7816403B2 (en) 1998-09-08 2010-10-19 University Of Utah Research Foundation Method of inhibiting ATF/CREB and cancer cell growth and pharmaceutical compositions for same
WO2000018392A1 (en) 1998-09-25 2000-04-06 Glycox Corporation Limited Fructosamine oxidase: antagonists and inhibitors
AU772026B2 (en) 1998-09-25 2004-04-08 Protemix Corporation Limited Fructosamine oxidase: antagonists and inhibitors
CN1324931A (zh) 2000-05-19 2001-12-05 上海博德基因开发有限公司 一种新的多肽——多铜氧化酶12和编码这种多肽的多核苷酸
RU2183961C1 (ru) 2001-08-27 2002-06-27 Новицкий Юрий Алексеевич Средство гидросульфат графито-металлический комплекс и способ лечения заболеваний кожи (их варианты)
WO2003054145A2 (en) 2001-11-09 2003-07-03 University Of Maryland, College Park Dinuclear copper-based compound and ligand for nucleic acid scission and anticancer treatment
WO2003052058A2 (en) 2001-11-09 2003-06-26 University Of Maryland, College Park Dinuclear copper-based compound and ligand for nucleic acid scission and anticancer treatment
JP4860906B2 (ja) 2002-03-08 2012-01-25 プロテミックス コーポレイション リミティド 心疾患および／または関連心不全の予防および／または治療
WO2004017957A1 (en) 2002-08-20 2004-03-04 Protemix Corporation Limited Preventing and/or treating cardiovascular disease and/or associated heart failure
CN1688301A (zh) * 2002-08-20 2005-10-26 普罗特米克斯公司 药物剂型及相关的治疗用途
CA2875522A1 (en) 2002-08-20 2004-03-04 Philera New Zealand Limited Dosage forms and related therapies
KR20050074997A (ko) 2002-11-15 2005-07-19 아레스 트레이딩 에스.에이. Ｉｍａｃ를 이용한 ｔｎｆ-결합 단백질의 정제 방법
CN1194668C (zh) 2003-07-11 2005-03-30 马驷 纳米铜粉作为制备免疫增强药物的应用
EP1694317A4 (en) 2003-12-19 2010-05-12 Protemix Corp Ltd COPPER ANTAGONIST COMPOUNDS
US20080031817A1 (en) 2004-02-24 2008-02-07 Mazar Andrew P Inhibition Of Superoxide Dismutase By Tetrathiomolybdate: Identification Of New Anti-Angiogenic And Antitumor Agents
CA2875095C (en) 2004-07-19 2019-09-03 Philera New Zealand Limited Synthesis of triethylenetetramines
US7618615B2 (en) * 2004-08-13 2009-11-17 Healthpartners Research Foundation Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia
DE102004056727A1 (de) 2004-11-24 2006-06-01 Cavira Biopharmaceuticals Ag Kupfer-Melphalan und Kupfer-Tegafur als Antitumormittel
WO2006104401A1 (en) * 2005-03-26 2006-10-05 Protemix Corporation Limited Copper antagonist compositions
US20110136157A1 (en) * 2005-04-25 2011-06-09 Garth James Smith Cooper Copper regulation evaluation and therapy
GB0513812D0 (en) 2005-07-05 2005-08-10 Isis Innovation Compounds for imaging and therapy
AU2006312407A1 (en) 2005-11-09 2007-05-18 Philera New Zealand Limited Treatment of mitochondria-related diseases and improvement of age-related metabolic deficits
US7867522B2 (en) 2006-09-28 2011-01-11 Jr Chem, Llc Method of wound/burn healing using copper-zinc compositions
CN100436457C (zh) * 2006-12-01 2008-11-26 周成勇 N1,n8－二取代的三乙基四胺合铜(ⅱ)配合物及其制备方法
CN101322825A (zh) 2007-06-15 2008-12-17 王振军 一种治疗恶性肿瘤的药物组合物
RU2392668C1 (ru) 2008-12-15 2010-06-20 Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Росмедтехнологий" Способ индукции антипролиферативного, цитотоксического эффекта в опухолевых клетках линейных и свежевыделенных культур
US8999294B2 (en) 2010-06-23 2015-04-07 The Board Of Regents Of The University Of Texas System Nanoparticles for use in tumor diagnosis and therapy
CN101991665B (zh) 2010-11-15 2012-05-09 张景红 治疗扩张型心肌病、股骨头坏死和肿瘤的组合物及其制备工艺
EP2966061B1 (en) 2011-03-04 2017-05-03 Life Technologies Corporation Compounds and methods for conjugation of biomolecules
WO2012134822A1 (en) 2011-03-28 2012-10-04 Memorial Sloan-Kettering Cancer Center Allosteric reversible pan-caspase inhibitors
CN102274347B (zh) 2011-07-15 2013-11-06 陈迪 抗癌组合物
CN102357100A (zh) 2011-10-12 2012-02-22 沈阳药科大学 抗肿瘤联合药物
CN102614191A (zh) 2012-02-29 2012-08-01 吉林大学 硫杂杯芳烃金属配合物的合成及作为抗癌药物的用途
CN103467577B (zh) * 2012-06-08 2015-07-08 四川大学华西医院 一种短肽、载铜纳米生物材料及在制备治疗下肢缺血性疾病的药物中的应用
US9597406B2 (en) 2012-08-28 2017-03-21 Original BioMedicals Co., Ltd Controlled release method for a pharmaceutical composition composed of chelating complex micelles
JP6449537B2 (ja) 2012-12-27 2019-01-09 日本メジフィジックス株式会社 抗腫瘍剤、及び、抗腫瘍用キット
CN105189474A (zh) 2013-01-23 2015-12-23 芝加哥大学 用于抑制人铜转运蛋白atox1和ccs的方法和组合物
CN103265452B (zh) 2013-05-29 2014-04-09 福州大学 一种希夫碱配体和其铜配合物及应用
CN103467497B (zh) 2013-09-03 2016-04-13 广西师范大学 以水杨醛缩牛磺酸和咪唑为配体的双配体铜配合物及其合成方法和其用途
CN103788118B (zh) 2014-02-21 2016-05-25 南开大学 单核铜配合物及其制备方法和应用
CN103951602B (zh) 2014-03-19 2016-06-15 河南理工大学 具有抗肿瘤活性的吡咯缩氨基硫脲铜、镍配合物的合成方法
CN103936772A (zh) 2014-05-05 2014-07-23 河南理工大学 一种具有抗肿瘤活性的双核铜配合物的制备方法
CN105753719B (zh) 2014-12-17 2019-06-21 四川科瑞德凯华制药有限公司 一种盐酸曲恩汀化合物
WO2016168993A1 (en) 2015-04-22 2016-10-27 Innolife Co., Ltd. Methods of tissue repair and regeneration
WO2017049529A1 (en) 2015-09-24 2017-03-30 Innolife Co., Ltd. A pharmaceutical composition comprising a copper chelating tetramine and the use thereof

Also Published As

Publication number Publication date
US20180296598A1 (en) 2018-10-18
CO2018004189A2 (es) 2018-07-19
CN117338762A (zh) 2024-01-05
CA2998958A1 (en) 2017-03-30
WO2017050271A1 (en) 2017-03-30
MX2018003434A (es) 2018-11-09
CA2998958C (en) 2020-12-22
AU2016328156A1 (en) 2018-04-12
CN108697669A (zh) 2018-10-23
CL2018000742A1 (es) 2018-11-09
ECSP18031122A (es) 2018-05-31
CN108697669B (zh) 2023-08-15
IL257904B (en) 2021-04-29
US20210379102A1 (en) 2021-12-09
EP3352743A4 (en) 2019-07-03
IL257904A (en) 2018-05-31
EA037045B1 (ru) 2021-01-29
HK1259032A1 (zh) 2019-11-22
AU2016328156B2 (en) 2022-03-17
US12076340B2 (en) 2024-09-03
US11033579B2 (en) 2021-06-15
JP7041053B2 (ja) 2022-03-23
UA123503C2 (uk) 2021-04-14
JP2018531931A (ja) 2018-11-01
MX391462B (es) 2025-03-21
NZ740728A (en) 2019-07-26
BR112018005638A2 (pt) 2018-10-09
WO2017049529A1 (en) 2017-03-30
EA201890753A1 (ru) 2018-08-31
EP3352743A1 (en) 2018-08-01
KR20180055877A (ko) 2018-05-25

Similar Documents

Publication Publication Date Title
ECSP18031122A (es) Uso de trientina para el suministro de cobre a un tejido isquémico
CL2018003597A1 (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores delrrk2 para el uso en el tratamiento de trastornos neurodegenerativos.
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
MX2024013963A (es) Un antagonista de il-4r util para el tratamiento o la prevencion del asma
CL2018000897A1 (es) Composicion de fortalecimiento del cabello y metodo para fortalecer el cabello.
CO2017001493A2 (es) Kits que comprenden inhibidores tigit y agentes anticáncer
UY37435A (es) Pirrolidinas sustituidas y métodos para usarlas
MX2018005829A (es) Composiciones para tratar el cabello.
MX2017004906A (es) Dihidropirrolopiridinas inhibidoras del receptor huerfano-gamma.
UY36342A (es) Nuevos derivados de aminoalquilbenzotiazepinas y usos de los mismos
GT201600183A (es) Compuestos orgánicos de monobactam para el tratamiento de infecciones bacterianas
ECSP17018120A (es) Triazolopirazinonas como inhibidores de pde1
MX2016016583A (es) Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas.
MX2017000142A (es) Celulas estromales mesenquimatosas para tratar el sindrome de respuesta inflamatoria sistemica.
MX2017016347A (es) Terapia de combinacion de activador de miosina cardiaca e inhibidor de corriente if del nodo sinusal.
CR20160316A (es) Compuestos derivados de hidroxiformamida y usos del mismo
DOP2017000146A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CL2017002299A1 (es) Combinaciones de dosis fija y formulaciones comprendiendo etc-1002 y ezetimiba y métodos para tratar o reducir el riesgo de enfermedades cardiovasculares
MX2018005158A (es) Compuestos para el tratamiento de trastornos hipoproliferativos.
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
SV2016005293A (es) Compuestos de azol amido-sustituidos como inhibidores de tnks1 y/o tnks2
CR20170090A (es) Derivados de terahidroquinolina como inhibidores del bromodominio
GT201700016A (es) [1,2,4] triazolo [4,3 -b] piridazinas para su uso en el tratamiento de enfermedades proliferativas
ECSP16082599A (es) Quinazolin-thf-aminas halogenadas como inhibidores de pde1
GT201500056S (es) Aparato para peinar el cabello